• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血清人附睾蛋白 4 检测在卵巢癌诊断中的临床价值：一项荟萃分析。

Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.

机构信息

Department of Gynecologic Oncology, Guangxi Medical University, Nanning, People's Republic of China.

出版信息

Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Print 2013.

DOI:10.2147/OTT.S45681
PMID:23901285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3726590/
Abstract

OBJECTIVE

Human epididymis protein 4 (HE4) has been approved for diagnosing ovarian cancer. The goal of this meta-analysis was to evaluate the clinical value of the serum HE4 in the diagnosis of ovarian cancer.

METHODS

The PubMed and Embase databases were searched to identify suitable studies. The sensitivity (SEN), specificity (SPE), and positive and negative likelihood ratios (PLR and NLR, respectively) of HE4 for the diagnosis of ovarian cancer were commonly used as bivariates. Summary receiver operating characteristic curves were used to summarize overall test performances. Meta-Disc 1.4 software was used to analyze the data.

RESULTS

A total of 6,269 patients from 31 trials were subjected to meta-analysis. The summary estimates of HE4 for ovarian cancer diagnosis were as follows: SEN 0.73 (95% confidence interval [CI] 0.71-0.75); SPE 0.89 (95% CI 0.88-0.90); PLR 7.30 (95% CI 5.42-9.84); and NLR 0.15 (95% CI 0.10-0.23). SEN 0.74 (95% CI 0.72-0.76); SPE 0.89 (95% CI 0.88-0.90); PLR 7.35 (95% CI 5.55-9.73); NLR 0.14 (95% CI 0.09-0.21).

CONCLUSION

Our study demonstrates that the sensitivity and specificity of HE4 was higher than that of cancer antigen 125. The results indicated that HE4 could be a useful tumor marker for ovarian cancer diagnosis. However, the results of this meta-analysis should be interpreted with caution, due to the heterogeneity among study designs. Further study should pay more attention to the possibility that HE4 can be a marker for monitoring recurrence of ovarian cancer.

摘要

目的

人附睾蛋白 4（HE4）已被批准用于诊断卵巢癌。本荟萃分析的目的是评估血清 HE4 在卵巢癌诊断中的临床价值。

方法

检索 PubMed 和 Embase 数据库以确定合适的研究。常用血清 HE4 对卵巢癌诊断的敏感性（SEN）、特异性（SPE）、阳性和阴性似然比（PLR 和 NLR）作为双变量进行分析。汇总受试者工作特征曲线用于总结整体检测性能。使用 Meta-Disc 1.4 软件分析数据。

结果

共有 31 项试验的 6269 名患者进行了荟萃分析。HE4 对卵巢癌诊断的汇总估计值如下：SEN 为 0.73（95%置信区间[CI] 0.71-0.75）；SPE 为 0.89（95%CI 0.88-0.90）；PLR 为 7.30（95%CI 5.42-9.84）；NLR 为 0.15（95%CI 0.10-0.23）。SEN 为 0.74（95%CI 0.72-0.76）；SPE 为 0.89（95%CI 0.88-0.90）；PLR 为 7.35（95%CI 5.55-9.73）；NLR 为 0.14（95%CI 0.09-0.21）。

结论

本研究表明，HE4 的敏感性和特异性均高于癌抗原 125。结果表明 HE4 可能是卵巢癌诊断的有用肿瘤标志物。然而，由于研究设计的异质性，应谨慎解释本荟萃分析的结果。进一步的研究应更多地关注 HE4 作为监测卵巢癌复发的标志物的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/c272b5f93748/ott-6-957Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/e76648448463/ott-6-957Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/68a78c2d53f0/ott-6-957Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/37ec831b75d8/ott-6-957Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/d16ad643f175/ott-6-957Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/e1294a541073/ott-6-957Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/455bf9e3148f/ott-6-957Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/c272b5f93748/ott-6-957Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/e76648448463/ott-6-957Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/68a78c2d53f0/ott-6-957Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/37ec831b75d8/ott-6-957Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/d16ad643f175/ott-6-957Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/e1294a541073/ott-6-957Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/455bf9e3148f/ott-6-957Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee6/3726590/c272b5f93748/ott-6-957Fig7.jpg

相似文献

1
Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.血清人附睾蛋白 4 检测在卵巢癌诊断中的临床价值：一项荟萃分析。
Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Print 2013.
2
Diagnostic value of serum human epididymis protein 4, carbohydrate antigen 125 and their combination in endometrial cancer: A meta-analysis.血清人附睾蛋白 4、糖链抗原 125 及其联合检测对子宫内膜癌的诊断价值：一项荟萃分析。
Medicine (Baltimore). 2023 Aug 18;102(33):e34737. doi: 10.1097/MD.0000000000034737.
3
Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis.人附睾蛋白4与间皮素相比对卵巢癌的诊断价值：一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2012;13(11):5427-32. doi: 10.7314/apjcp.2012.13.11.5427.
4
Diagnostic value of HE4 in ovarian cancer: A meta-analysis.人附睾蛋白4在卵巢癌中的诊断价值：一项荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2018 Dec;231:35-42. doi: 10.1016/j.ejogrb.2018.10.008. Epub 2018 Oct 4.
5
Meta-analysis of the diagnostic accuracy of HE4 for endometrial carcinoma.人附睾蛋白4对子宫内膜癌诊断准确性的Meta分析。
Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:404-411. doi: 10.1016/j.ejogrb.2020.07.015. Epub 2020 Jul 15.
6
The diagnostic accuracy of HE4 in lung cancer: a meta-analysis.人附睾蛋白4（HE4）在肺癌诊断中的准确性：一项荟萃分析。
Dis Markers. 2015;2015:352670. doi: 10.1155/2015/352670. Epub 2015 Mar 19.
7
Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.血清人附睾蛋白4与糖类抗原125作为卵巢癌标志物的比较：一项荟萃分析。
Mol Clin Oncol. 2014 Jul;2(4):559-566. doi: 10.3892/mco.2014.279. Epub 2014 Apr 16.
8
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.卵巢恶性肿瘤风险算法是否优于人附睾蛋白 4 和 CA125 预测上皮性卵巢癌：一项荟萃分析。
BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.
9
Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis.人附睾蛋白 4 用于良恶性妇科疾病鉴别诊断及卵巢癌中的研究：系统评价与荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):81-5. doi: 10.1016/j.ejogrb.2012.10.036. Epub 2012 Dec 7.
10
The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.人附睾蛋白 4（HE4）在鉴别良恶性盆腔肿块中的诊断准确性：系统评价和荟萃分析。
Acta Obstet Gynecol Scand. 2021 Oct;100(10):1788-1799. doi: 10.1111/aogs.14224. Epub 2021 Jul 19.

引用本文的文献

1
Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer.使用肿瘤标志物人附睾蛋白4对卵巢癌患者进行随访观察的评估。
Obstet Gynecol Sci. 2023 Jul;66(4):290-299. doi: 10.5468/ogs.23024. Epub 2023 Jun 28.
2
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.蛋白质组学在卵巢癌中的应用：新时代的曙光。
Proteomes. 2022 May 9;10(2):16. doi: 10.3390/proteomes10020016.
3
The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.

本文引用的文献

1
Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?评估 HE4 作为 CA125 的额外生物标志物以提高卵巢癌的检测：是否是向前迈进的一步？
Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.
2
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 评估与 CA125 比较在卵巢癌诊断和治疗反应评估中的意义。
Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.
3
Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
人附睾蛋白4在疾病诊断和预后中的作用：观察性研究的系统评价和荟萃分析的伞状综述
Front Med (Lausanne). 2022 Mar 24;9:842002. doi: 10.3389/fmed.2022.842002. eCollection 2022.
4
Current clinical application of serum biomarkers to detect and monitor ovarian cancer - update.血清生物标志物在卵巢癌检测和监测中的当前临床应用——最新进展
Prz Menopauzalny. 2021 Dec;20(4):211-216. doi: 10.5114/pm.2021.112474. Epub 2022 Jan 6.
5
Modified HE4, CA125, and ROMA cut-off values and predicted probability of ovarian tumor in Chinese patients.中国患者中改良的HE4、CA125及ROMA截断值与卵巢肿瘤预测概率
Gland Surg. 2021 Nov;10(11):3097-3105. doi: 10.21037/gs-21-666.
6
Biomarkers and Strategies for Early Detection of Ovarian Cancer.卵巢癌的早期检测的生物标志物和策略。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512. doi: 10.1158/1055-9965.EPI-20-1057. Epub 2020 Oct 13.
7
HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis.人附睾蛋白4作为肺癌诊断生物标志物的Meta分析
Medicine (Baltimore). 2019 Sep;98(39):e17198. doi: 10.1097/MD.0000000000017198.
8
The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction.人附睾蛋白4作为肾功能不全患者新型生物标志物的诊断价值。
Int Urol Nephrol. 2018 Nov;50(11):2043-2048. doi: 10.1007/s11255-018-1930-x. Epub 2018 Jul 13.
9
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.携带BRCA1基因突变的患者在接受预防性手术时以及其他良性和恶性妇科疾病患者的血清HE4水平
Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.
10
Current clinical application of serum biomarkers to detect ovarian cancer.血清生物标志物在卵巢癌检测中的当前临床应用。
Prz Menopauzalny. 2015 Dec;14(4):254-9. doi: 10.5114/pm.2015.55887. Epub 2015 Nov 27.
HE4、CA125 和 ROMA 算法在盆腔肿块女性中的比较：与病理结果的相关性。
Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.
4
Diagnostic value of HE4 for ovarian cancer: a meta-analysis.HE4 对卵巢癌的诊断价值：一项荟萃分析。
Clin Chem Lab Med. 2012 Feb 3;50(8):1439-46. doi: 10.1515/cclm-2011-0477.
5
Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis.血清人附睾蛋白 4（HE4）在卵巢癌中的诊断价值：系统评价和荟萃分析。
Int J Gynecol Cancer. 2012 Sep;22(7):1106-12. doi: 10.1097/IGC.0b013e318263efa2.
6
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.评估 HE4、CA125、卵巢恶性肿瘤风险算法（ROMA）和恶性肿瘤指数（RMI）在盆腔肿块患者中作为上皮性卵巢癌的诊断工具。
Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.
7
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.卵巢恶性肿瘤风险算法是否优于人附睾蛋白 4 和 CA125 预测上皮性卵巢癌：一项荟萃分析。
BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.
8
Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.血清 HE4 作为一种有用的生物标志物，可用于区分卵巢癌与良性盆腔疾病。
Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.
9
The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.人附睾蛋白 4、癌抗原 125 及恶性肿瘤风险算法在卵巢癌和子宫内膜异位症中的应用。
Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.
10
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.血清人附睾蛋白 4 和卵巢恶性肿瘤算法作为上皮性卵巢癌管理的新的诊断和预后工具。
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.